In reading over the review of melatonin, this paragraph particularly struck me.
Melatonin has a protective effect on the cholinergic system. It prevents the peroxynitrite-induced
inhibition of choline transport and ChAT activity in synaptosomes and synaptic vesicles [126].
Melatonin treatment of eight-month-old APP695 transgenic mice significantly improved the profound
reduction in ChAT activity in the frontal cortex and the hippocampus [81]. Melatonin also antagonizes
the spatial memory deficit and the decreased ChAT activity found in adult ovariectomized rats [127].
However, in rats perfused intracerebroventricularly with Aβ for 14 days, melatonin was unable to
restore ChAT activity [128]. Melatonin inhibited lipopolysaccharide- and streptozotocin-induced
increase in AChE activity [129]. Recently hybrids of the AChE inhibitor tacrine and melatonin were
synthesized as new drug candidates for treating AD [130,131]. These hybrids showed better
antioxidant and cholinergic-preserving activity than tacrine or melatonin alone. The direct intracerebral
administration of one of these hybrids decreased induced cell death and Aβ load in the APP/PS1
mouse brain parenchyma accompanied by a recovery of cognitive function [131].
My thinking is that many of these compounds (such as melatonin, ferulic acid, and curcumin, for instance)/drugs (pbt2, for instance) show efficacy in certain areas in mice and in human beings, but when applied to humans they seem to fall just a bit short when it comes to cognitive function. There may be great potential for hybrids, natural compounds containing multiple antioxidants, and/or compounds that are highly concentrated and can be inhaled almost directly into the brain (various essential oils via aromatherapy) to get you over that last hump.
- Forums
- ASX - By Stock
- I don't know! Maybe...
In reading over the review of melatonin, this paragraph...
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ATH (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.5¢ |
Change
0.001(25.0%) |
Mkt cap ! $26.19M |
Open | High | Low | Value | Volume |
0.5¢ | 0.5¢ | 0.5¢ | $27.94K | 6.050M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
46 | 57663299 | 0.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.5¢ | 56205001 | 43 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
46 | 57663299 | 0.004 |
74 | 84174813 | 0.003 |
19 | 29345125 | 0.002 |
15 | 81865101 | 0.001 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.005 | 56205001 | 43 |
0.006 | 17905330 | 28 |
0.007 | 9388861 | 18 |
0.008 | 7693109 | 15 |
0.009 | 4646078 | 9 |
Last trade - 16.10pm 29/03/2024 (20 minute delay) ? |
|
|||||
Last
0.5¢ |
  |
Change
0.001 ( 0.00 %) |
|||
Open | High | Low | Volume | ||
0.5¢ | 0.5¢ | 0.5¢ | 20524121 | ||
Last updated 15.46pm 29/03/2024 ? |
Featured News
ATH (ASX) Chart |
The Watchlist
BGD
BARTON GOLD HOLDINGS LIMITED
Alex Scanlon, Managing Director & CEO
Alex Scanlon
Managing Director & CEO
SPONSORED BY The Market Online